ReviewNature reviews. Clinical oncology2015
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.
- Pooled it
- Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Breast cancer research and treatment · 2023Trial
- Bioequivalence Study of Palbociclib Capsules in Healthy Chinese Subjects Under Fasting and Fed Conditions.Clinical drug investigation · 2022Trial
- Trial
- Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial.Cancer medicine · 2019Trial
- Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death.Journal for immunotherapy of cancer · 2026Article
- Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.BMC cancer · 2026Article
- Unveiling the cytotoxic potential of four Callistemon fruit extracts against breast and colon cancer: a combined metabolomic and in silico approach.BMC complementary medicine and therapies · 2026Article
- CDK4/6 inhibitor rechallenge therapy in advanced breast cancer.Discover oncology · 2025Review
- Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.bioRxiv : the preprint server for biology · 2025Article
- Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors.Nature communications · 2025Article
- Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.bioRxiv : the preprint server for biology · 2025Article
- PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.International journal of clinical oncology · 2025Article
- linc01152 Regulates Cell Viability, Cell Migration and Cell Invasion of Breast Cancer via Regulating miR-320a and MTDH.Biochemical genetics · 2025Article
- Real-World, National Study of Palbociclib in HR+/HER2- Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluation of circulating glypican 4 as a novel biomarker in disease - A comprehensive review.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Dual Biomarker Strategies for Liquid Biopsy: Integrating Circulating Tumor Cells and Circulating Tumor DNA for Enhanced Tumor Monitoring.Biosensors · 2025Review
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events.PloS one · 2025Article
- Epidemiology of early vs late recurrence among women with early stage estrogen receptor-positive breast cancer in the Pathways Study.Journal of the National Cancer Institute · 2024Article
- Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study.International journal of clinical oncology · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone-receptor-positive breast cancer accounts for the majority-up to 80%-of all breast cancers. The evolution of breast cancer from early stage to the metastatic setting leads to increased heterogeneity, the occurrence of new mutations, and the development of treatment resistance representing a great challenge for management decisions. Unfortunately, little data exist to offer guidance in this context, and a reliance on traditional clinical parameters remains when deciding on optimal treatment. In advanced-stage oestrogen receptor-positive (ER+) disease, ongoing issues include the choice between endocrine therapy and chemotherapy, the appropriate sequence of treatment agents, and the incorporation of biological agents, such as everolimus, into the treatment armamentarium. In metastatic disease, repeated biopsies can help to reassess the receptor or genetic mutational status; however, the evidence to support this approach is limited. In this Review, we examine the current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer, discuss how to tackle these therapeutic challenges and provide suggestions for the optimal management of this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.